HAIXI PHARMA (02637): Zhang Mingqiang appointed as Chief Research and Global Affairs Officer.

19:07 01/03/2026

HSRX Pharma (02637) announced that Zhang Mingqiang has been appointed as the Group's Chief R&D and Global Affairs Officer, effective from March 1, 2026.

HAIXI PHARMA (02637) announced that Zhang Mingqiang has been appointed as the Chief Research and Global Affairs Officer of the group, effective from March 1, 2026.

HAO WEN HLDGS (08019) Enters into a Supplementary Memorandum of Understanding with Chengmai Junli

ZJ UNITED INV (08366): Fu Enming appointed as authorized representative

YU TAK INT'L (08048) announced its mid-year performance for 2025, with a net loss attributable to shareholders of HK$1.049 million, a year-on-year decrease of 83.26%.

HAO WEN HLDGS (08019) Enters into a Supplementary Memorandum of Understanding with Chengmai Junli

ZJ UNITED INV (08366): Fu Enming appointed as authorized representative

YU TAK INT'L (08048) announced its mid-year performance for 2025, with a net loss attributable to shareholders of HK$1.049 million, a year-on-year decrease of 83.26%.